NYSE:PRGO - Perrigo Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $48.67 +0.52 (+1.08 %) (As of 03/19/2019 06:00 AM ET)Previous Close$48.15Today's Range$47.22 - $49.0852-Week Range$36.28 - $84.94Volume1.03 million shsAverage Volume1.51 million shsMarket Capitalization$6.61 billionP/E Ratio10.70Dividend Yield1.58%Beta1.31 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments. It offers OTC products in cough, cold, allergy, sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, animal health, diagnostic, lifestyle, personal care and derma-therapeutics, natural health and vitamins, and anti-parasite categories. The company also develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectables, hormones, oral solid dosage forms, and oral liquid formulations. In addition, it offers contract manufacturing services. The company offers its products through retail drug, supermarket, and mass merchandise chains; hospitals; pharmacies; wholesalers; drug and grocery stores; and para pharmacies, as well as through a network of pharmacy sales force in North America, Europe, Australia, Israel, and China. Perrigo Company plc has a collaborative agreement with the Sol-Gel Technologies Ltd. for the development, manufacturing, and commercialization of an ivermectin cream in the United States. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland. Receive PRGO News and Ratings via Email Sign-up to receive the latest news and ratings for PRGO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry N/A Sub-IndustryPharmaceuticals SectorMedical Current SymbolNYSE:PRGO Previous Symbol CUSIP71429010 CIK1585364 Webwww.perrigo.com Phone353-1709-4000Debt Debt-to-Equity Ratio0.54 Current Ratio1.89 Quick Ratio1.32Price-To-Earnings Trailing P/E Ratio10.70 Forward P/E Ratio10.89 P/E Growth2.07 Sales & Book Value Annual Sales$4.73 billion Price / Sales1.40 Cash Flow$7.9267 per share Price / Cash Flow6.14 Book Value$41.72 per share Price / Book1.17Profitability EPS (Most Recent Fiscal Year)$4.55 Net Income$131 million Net Margins2.77% Return on Equity10.74% Return on Assets5.62%Miscellaneous Employees10,400 Outstanding Shares135,873,000Market Cap$6.61 billion Next Earnings Date5/14/2019 (Estimated) OptionableOptionable Perrigo (NYSE:PRGO) Frequently Asked Questions What is Perrigo's stock symbol? Perrigo trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRGO." How often does Perrigo pay dividends? What is the dividend yield for Perrigo? Perrigo announced a quarterly dividend on Thursday, February 14th. Stockholders of record on Friday, March 1st will be given a dividend of $0.19 per share on Tuesday, March 19th. This represents a $0.76 dividend on an annualized basis and a dividend yield of 1.56%. The ex-dividend date of this dividend is Thursday, February 28th. View Perrigo's Dividend History. How were Perrigo's earnings last quarter? Perrigo Company PLC (NYSE:PRGO) released its earnings results on Wednesday, February, 27th. The company reported $0.97 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $1.00 by $0.03. The firm had revenue of $1.20 billion for the quarter, compared to analysts' expectations of $1.18 billion. Perrigo had a net margin of 2.77% and a return on equity of 10.74%. Perrigo's revenue was down 6.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.28 EPS. View Perrigo's Earnings History. When is Perrigo's next earnings date? Perrigo is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Perrigo. What price target have analysts set for PRGO? 13 Wall Street analysts have issued 1 year target prices for Perrigo's stock. Their forecasts range from $47.00 to $110.00. On average, they anticipate Perrigo's share price to reach $77.2857 in the next twelve months. This suggests a possible upside of 58.8% from the stock's current price. View Analyst Price Targets for Perrigo. What is the consensus analysts' recommendation for Perrigo? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Perrigo in the last year. There are currently 1 sell rating, 10 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Perrigo. Has Perrigo been receiving favorable news coverage? Media stories about PRGO stock have been trending somewhat negative on Tuesday, according to InfoTrie. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Perrigo earned a news sentiment score of -1.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. Who are some of Perrigo's key competitors? Some companies that are related to Perrigo include ESSILOR INTL S/S (ESLOY), Zimmer Biomet (ZBH), Centene (CNC), Eisai (ESALY), Fresenius Medical Care AG & Co. (FMS), TERUMO CORP/ADR (TRUMY), McKesson (MCK), LONZA GRP AG/ADR (LZAGY), Fresenius Medical Care AG & Co. KGaA (FME), COLOPLAST A/S/ADR (CLPBY), Canopy Growth (WEED), Align Technology (ALGN), Cerner (CERN), IDEXX Laboratories (IDXX) and Incyte (INCY). What other stocks do shareholders of Perrigo own? Based on aggregate information from My MarketBeat watchlists, some companies that other Perrigo investors own include Teva Pharmaceutical Industries (TEVA), Gilead Sciences (GILD), Celgene (CELG), Twitter (TWTR), Mylan (MYL), Allergan (AGN), General Electric (GE), Amgen (AMGN), Intel (INTC) and Starbucks (SBUX). Who are Perrigo's key executives? Perrigo's management team includes the folowing people: Mr. Ronald L. Winowiecki, Chief Financial Officer (Age 53)Mr. Todd W. Kingma, Exec. VP, Gen. Counsel & Sec. (Age 59)Mr. Sharon Kohan, Exec. VP & Pres of Branded Consumer Healthcare and International (Age 51)Mr. Jeffrey R. Needham, Exec. VP & Pres of Consumer Healthcare Americas (Age 63)Mr. Murray S. Kessler, CEO, Pres & Director (Age 59) Who are Perrigo's major shareholders? Perrigo's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.23%), FMR LLC (5.96%), Clal Insurance Enterprises Holdings Ltd (1.74%), Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management (1.29%), Geode Capital Management LLC (1.24%) and Geode Capital Management LLC (1.24%). Company insiders that own Perrigo stock include Geoffrey M Parker, Jeffrey C Smith, Jeffrey Needham, John Wesolowski, Murray S Kessler, Sharon Kochan, Svend Andersen, Thomas Farrington, Todd W Kingma and Uwe Roehrhoff. View Institutional Ownership Trends for Perrigo. Which institutional investors are selling Perrigo stock? PRGO stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Victory Capital Management Inc., Iridian Asset Management LLC CT, Parnassus Investments CA, Manning & Napier Group LLC, Mackenzie Financial Corp, Menora Mivtachim Holdings LTD. and Canada Pension Plan Investment Board. View Insider Buying and Selling for Perrigo. Which institutional investors are buying Perrigo stock? PRGO stock was acquired by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, Norges Bank, Dimensional Fund Advisors LP, Clal Insurance Enterprises Holdings Ltd, First Trust Advisors LP, Geode Capital Management LLC, Geode Capital Management LLC and TD Asset Management Inc.. Company insiders that have bought Perrigo stock in the last two years include Geoffrey M Parker, Jeffrey C Smith, John Wesolowski, Murray S Kessler, Svend Andersen, Todd W Kingma and Uwe Roehrhoff. View Insider Buying and Selling for Perrigo. How do I buy shares of Perrigo? Shares of PRGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Perrigo's stock price today? One share of PRGO stock can currently be purchased for approximately $48.67. How big of a company is Perrigo? Perrigo has a market capitalization of $6.61 billion and generates $4.73 billion in revenue each year. The company earns $131 million in net income (profit) each year or $4.55 on an earnings per share basis. Perrigo employs 10,400 workers across the globe. What is Perrigo's official website? The official website for Perrigo is http://www.perrigo.com. How can I contact Perrigo? Perrigo's mailing address is THE SHARP BUILDING HOGAN PLACE, DUBLIN L2, 49010. The company can be reached via phone at 353-1709-4000 or via email at [email protected] MarketBeat Community Rating for Perrigo (NYSE PRGO)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 661 (Vote Outperform)Underperform Votes: 628 (Vote Underperform)Total Votes: 1,289MarketBeat's community ratings are surveys of what our community members think about Perrigo and other stocks. Vote "Outperform" if you believe PRGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRGO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/19/2019 by MarketBeat.com StaffFeatured Article: What are trading strategies for the 52-week high/low?